top of page

Advanced intraperitoneal drug solutions for oncology

Long acting therapeutics for the life threatening peritoneal diseases

UPyTher’s hydrogel technology
Peritoneal carcinomatosis Metastases to the peritoneum
Pipetting Monsters

Peritoneal carcinomatosis

Metastases to the peritoneum

Peritoneal carcinomatosis is a common, but underrated, type of cancer. Common cancers such as colorectal, gastric, and ovarian cancer are notorious for spreading to the peritoneal cavity and cause a substantial number of 1.3 million new cases of peritoneal carcinomatosis each year worldwide.

Metastases to the peritoneal cavity have the worst prognosis for patients with little chance of survival over a year and rapid decline of quality of life because current treatment modalities fail to adequately manage peritoneal disease.

Current treatment methods rely on traditional products that were developed for intravenous use. Efficacy of such products for the treatment of peritoneal carcinomatosis is hampered by poor drug delivery into the peritoneal cavity and inadequate – too short – duration of drug exposure.

Laboratorium

Innovative therapies to treat peritoneal carcinomatosis

Innovative therapies to treat peritoneal carcinomatosis

UPyTher is working to set a new standard of care in peritoneal oncology and make intraperitoneal therapy simple, safe and effective.

 

UPyTher’s solution is specifically designed for intraperitoneal administration and sustained release of medication in the peritoneal cavity for patients

Peritoneal carcinomatosis Metastases to the peritoneum
UPyTher’s hydrogel technology

UPyTher’s hydrogel technology is specifically designed for administration to the peritoneal cavity.

It can be injected as a liquid, distributes evenly in the abdomen and forms a drug depot

Innovative therapies to treat peritoneal carcinomatosis
Innovative therapies to treat peritoneal carcinomatosis

UPyTher’s products are instilled as a liquid and convert to a soft, elastic gel inside the body

Route of administration fits with current clinical practices

Increases dwell time and exposure of active drugs

Technology based on supramolecular
UPy-chemistry

Spreads throughout the peritoneal cavity to all tumor sites

Improving therapeutic effects of existing drugs as intraperitoneal therapy

Contact
Contact

Thank you for the submission!

istockphoto-617893290-612x612.jpg

Contact
UPyTher B.V. | Postbus 80 | 5600 AB Eindhoven | The Netherlands
Chamber of commerce: 72432195 
Mail: Please use contact form

Visiting address
(TU/e campus) Het Eeuwsel 57 | 5612 AS Eindhoven
building Alpha Hub | Office 2.24 

bottom of page